BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA)
Phase of Trial: Phase IV
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Golimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms BioTRAC
- Sponsors Janssen Inc; Merck & Co
- 17 Jun 2017 Results (n=188) assessing validation of new potential targets for remission in psoriatic arthritis presented at the 18th Annual Congress of the European League Against Rheumatism.
- 17 Jun 2017 Results assesseng incidence of disease worsening in nkylosing spondylitis and rheumatoid arthritis patients on long-term therapy (n= 621) presented at the 18th Annual Congress of the European League Against Rheumatism
- 13 Jun 2017 Planned End Date changed from 31 Dec 2020 to 17 Sep 2020.